Q&A Zealand Pharma 2022-03-22

	22/3 15:07 af Emmanuel Dulac	On the commercial front we will continue to build on the launch of Zegalogue and in the most recent symphony health data we were encouraged to see an uptick in the number of unique prescribers which indicted an over 30% increase per week compared to what we saw over the 4th quarter of 2021.
	22/3 15:07 af Emmanuel Dulac	Additionally, together with our partner Beta Bionics we expect to see the dosing of the first patient in our Phase 3 program of the iLet® bionic pancreas devise for the treatment of Type 1 diabetes…
	22/3 15:06 af Emmanuel Dulac	We also look forward to seeing results from the SAD portion of the Phase 1 trial with our amylin analogue ZP8396 and we intend to initiate the Phase 1b multiple ascending dose trial with this product later this year…
	22/3 15:06 af Emmanuel Dulac	In Obesity we recently announced that in our programme partnered with Boeringher Ingleheim - the Phase 2 with BI 456906 in people with type 2 diabetes - all subjects are randomized and we look forward to present the data later this year and see the data from the Phase 2 data in obesity. ..
	22/3 15:06 af Emmanuel Dulac	We expect to progress our pipeline during the year. Highlights will include two pivotal trial readouts - Glepaglutide in Short Bowel Syndrome (SBS) and dasiglucagon for Cogenital hyperinsulinism (CHI)….
	22/3 15:05 af Emmanuel Dulac	We will present further data on our Amylin analogue in obesity and expect to make good progress through Phase 1 in 2022.
	22/3 15:05 af Emmanuel Dulac	We expect to see considerable newsflow from the pipeline during 2022 – not least the Phase 3 readouts from trials with Glapaglutide in SBS and dasiglucagon in in CHI. Furthermore, our partner Borheinger Ingelheim will present Phase data on GLU-GLP1 in type 2 diabetes, and we should also see the Phase 2 data for this molecule in Obesity....
	22/3 15:04 af Emmanuel Dulac	We can divide our pipeline into four therapeutic areas with high unmet medical needs: Type 1 diabetes, rare diseases, obesity where we have products in mid and late-stage clinical development and Inflammation where we are in preclinical development….
	22/3 15:04 af Helge Larsen/PI-redaktør	Can you please give us an overview of the present Zealand Pharma pipeline?
	22/3 15:04 af Emmanuel Dulac	During 2022, we also expect revenue from existing license agreements but as such revenue is uncertain in terms of size and timing, we do not provide guidance on this.
	22/3 15:03 af Emmanuel Dulac	Our Financial Guidance for 2022 is that we expect net product revenue from the sales of commercial products to be DKK 235 million. Net operating expenses in 2022 are expected to be DKK 1,200 million. Both with a margin of plus or minus 10%....
	22/3 15:03 af Helge Larsen/PI-redaktør	What is the guidance for 2022?
	22/3 15:03 af Emmanuel Dulac	Total revenue for the year was 292.6 million DKK driven by net product revenue of the V-Go wearable insulin deliver device and Zegalague as well as partnership revenue from collaborations with Alexion, Boeringher Ingleheim and Sanofi. The net operating result was a loss of 1.05 billion DKK and net operating expenses were 1.22 billion DKK.
	22/3 15:03 af Emmanuel Dulac	We were pleased to announce non-dilutive financing with an agreement with Oberland Capital which includes an upfront payment of USD $100 million in exchange for a seven-year interest only secured note…
	22/3 15:02 af Emmanuel Dulac	demonstrating 13.7% weight loss after only 16 weeks of dosing. In our financials, we maintained a strong financial position and at the end of the year we had cash, cash equivalents and marketable securities of 1.4 billion DKK…
	22/3 15:02 af Emmanuel Dulac	We also completed enrollment in our pivotal Phase 3 trial with glepaglutide in patients with short bowel syndrome (SBS) and we look forward to readouts from this trial in the third quarter… In our earlier stage pipeline, we completed the Phase 1b trial of our GLP1-CLP2 dual agonist dapiglutide and started the dosing of patients in the Phase 1 obesity trial of our long-acting amylin analogue ZP8396. In the same area our partner Boehringer Ingelheim presented clinical data from our GLU-GLP1....
	22/3 15:01 af Emmanuel Dulac	2021 was a transformational year for Zealand. We received our first FDA approval and launched Zegalogue on the market. We continued to progress our late-stage pipeline by completing enrollment in the pivotal Phase 3 trial of dasiglucagon for the treatment of congenital hyperinsulinism (CHI) with results planned for the second quarter this year…
	22/3 15:01 af Emmanuel Dulac	Thanks, great to be with you too.
	22/3 15:00 af Helge Larsen/PI-redaktør	Can you please give us a short-term update on key figures and important events for Q4?
	22/3 15:00 af Helge Larsen/PI-redaktør	Hi Adam, Welcome.
	22/3 15:00 af Emmanuel Dulac	Thank you, it is a pleasure to be here. I am also pleased to be joined today by Adam Steensberg our Chief Medical Officer
	22/3 14:59 af Helge Larsen/PI-redaktør	Good afternoon, Emmanuel Dulac and welcome to Q&A with us here on ProInvestor.com. We are very happy to have you with us today - ready to answer a wide variety of questions from our investors.